kidney cancer

Sunitinib vs. everolimus: PFS, toxicity differ in studyIn a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
How renal mass biopsy impacts managementUrology Times SUO internship program member Robert M. Turner, II, MD, reports on a recent presentation by J. Stuart Wolf, Jr., MD, about possible pitfalls of renal mass biopsy.
Renal cancer follow-up: Find the happy mediumNurse practitioner Adele M. Caruso, MSN, CRNP, discusses appropriate timing of follow-up and ponders related health insurance coverage and cancer survivorship issues.
Renal biopsy may alter management in high-risk patientsIn this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
Study appears to refute obesity paradox in kidney cancerIn this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.
Opdivo approved for patients with metastatic renal cell carcinomaFDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.
Uro Pipeline: IDE approval granted for implantable neurostimulatorA prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
RCC trials don’t mirror real-world experienceStudy findings point to “a concept that has haunted clinical trialists for years,” says one expert.
Immunotherapy shows survival benefit in advanced RCCAn immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.
Best of AUA 2015: PCa surveillance, surgical controversies create buzzUrology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.